glp-1 receptor agonist and dpp-4 inhibitor combination not recommended DPP4 Inhibitors vs GLP-1 Agonists | June 2021 | Clinical Corner

SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study

21.65

★★★★☆4.8 (126)

Why are DPP-4 (Dipeptidyl Peptidase-4) inhibitors not typically combined with GLP-1 (Glucagon-Like Peptide-1) receptor agonists in patients with type 2 diabetes?

25.40

★★★★★4.9 (98)

GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes

26.78

★★★★★5.0 (157)

Frontiers

29.31

★★★★★4.7 (84)

GLP-1-RA and DPP-4 inhibitors in the management of type 2 diabetes

27.19

★★★★★4.9 (203)

GLP-1 receptor agonists should not be combined with DPP-4 inhibitors, as there is no added glucose-lowering benefit beyond that of the GLP-1 RA alone. Both drug classes work through overlapping mechanisms involving

25.50

★★★★★5.0 (176)

GLP-1 receptor agonists should not be combined with DPP-4 inhibitors, as there is no added glucose-lowering benefit beyond that of the GLP-1 RA alone. Both drug classes work through overlapping mechanisms involving

22.53

★★★★★4.8 (132)